Dianthus SVP granted 100,000 stock options

Dianthus Therapeutics granted its SVP, General Counsel and Secretary, Adam Veness, a stock option for 100,000 shares of common stock on February 3, 2026.

Accepted by SEC EDGAR 02/04/2026 - 05:41 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Dianthus Therapeutics granted its SVP, General Counsel and Secretary, Adam Veness, a stock option for 100,000 shares of common stock on February 3, 2026. The option has an exercise price of $52.46 per share and was reported as directly owned.

The underlying common shares will vest in equal monthly installments over four years after January 1, 2026, as long as Veness continues serving the company on each vesting date. Following this award, he beneficially owned 100,000 derivative securities linked to Dianthus common stock.

Insider Trade Summary

Grant/Award: 100,000 shares

Grant/Award 1 txn

Insider Veness Adam M

Role SVP, General Counsel and Sec.

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	100,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 100,000 contracts (Direct)

Footnotes (1)

1. F1. The shares of common stock underlying this stock option award will vest in equal monthly installments over the four years after January 1, 2026, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Dianthus Therapeutics (DNTH) report in Adam Veness's Form 4 filing?

Dianthus Therapeutics reported a stock option grant to SVP, General Counsel and Secretary Adam Veness for 100,000 shares on February 3, 2026. The option relates to common stock and is recorded as directly owned by Veness after the transaction.

What are the key terms of Adam Veness's 100,000-share stock option at Dianthus (DNTH)?

The stock option covers 100,000 shares of Dianthus common stock with an exercise price of $52.46 per share. It was granted on February 3, 2026 as a right to buy, and all 100,000 derivative securities are shown as directly owned afterward.

How does Adam Veness's Dianthus (DNTH) stock option vest over time?

The shares of common stock underlying the option vest in equal monthly installments over four years after January 1, 2026. Vesting is conditioned on Veness’s continued service to Dianthus on each monthly vesting date throughout that four-year period.

What is Adam Veness's role at Dianthus Therapeutics (DNTH) in this Form 4?

In the Form 4, Adam Veness is identified as an officer of Dianthus, serving as SVP, General Counsel and Secretary. He is not listed as a director or 10% owner, and the filing is made by one reporting person only.

How many Dianthus (DNTH) derivative securities does Adam Veness own after this Form 4 transaction?

After the reported transaction, Veness beneficially owns 100,000 derivative securities, all from this stock option grant. These derivatives correspond to 100,000 shares of Dianthus common stock, and the ownership form is reported as direct in the filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Veness Adam M

(Last) (First) (Middle)

C/O DIANTHUS THERAPEUTICS, INC.

7 TIMES SQUARE, 43RD FLOOR

(Street)

NEW YORK NY 10036

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Dianthus Therapeutics, Inc. /DE/ [ DNTH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, General Counsel and Sec.

3. Date of Earliest Transaction (Month/Day/Year)
02/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$52.46	02/03/2026		A		100,000		(1)	02/03/2036	Common Stock	100,000	$0	100,000	D

Explanation of Responses:

1. The shares of common stock underlying this stock option award will vest in equal monthly installments over the four years after January 1, 2026, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

	/s/ Adam Veness	02/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.